TrialScientific reports2018

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2- Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study.

Yannan Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.